Hospital
Methodist Health, INC.
Methodist Health, INC. was paid $1.32M by Medicaid between Jul 2019 and Sep 2021, across 76 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoMETHODIST HEALTH, INC.
MORGANFIELD, KY 42437
MORGANFIELD, KY 42437
33aNPI1174511620assigned 10/10/2005
33bProvider typeCritical Access Hospital
28Total paid$1.32M
24GClaims22,512
24DCodes billed76
24AFirst – last monthJul 2019 – Sep 2021
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#16 of 16
Median peer was paid$11.73M
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 312 | $11K | |
| 2020 | 5,163 | $287K | |
| 2021 | 17,037 | $1.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 1,069 | 776 | $384K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 1,543 | 1,239 | $275K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 347 | 225 | $143K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 191 | 138 | $54K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.1% | 1,048 | 268 | $54K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.8% | 575 | 489 | $37K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 535 | 368 | $31K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 37 | 32 | $29K |
| 80053 | Comprehensive metabolic panel | 1.9% | 2,357 | 1,467 | $26K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 2,814 | 1,368 | $24K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 363 | 246 | $20K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 318 | 249 | $19K |
64 more codes
| 80050 | General health panel | 1.5% | 443 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 2,061 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 15 | $13K |
| G0378 | Hospital observation service, per hour | <1% | 137 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 240 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 161 | $9K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 114 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 157 | $7K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 66 | $7K |
| 80061 | Lipid panel | <1% | 323 | $7K |
| 81001 | <1% | 941 | $7K | |
| 83735 | <1% | 573 | $6K | |
| 84439 | <1% | 430 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 244 | $5K |
| 83690 | <1% | 376 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 98 | $4K |
| 97014 | <1% | 112 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 75 | $4K |
| 86803 | <1% | 148 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 86 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 406 | $4K |
| 82607 | <1% | 98 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 33 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 35 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 253 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $3K |
| 73130 | <1% | 30 | $3K | |
| 82550 | <1% | 230 | $3K | |
| 87040 | <1% | 113 | $2K | |
| 82553 | <1% | 145 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 182 | $2K |
| 83605 | <1% | 121 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 161 | $2K |
| 73630 | <1% | 14 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 84 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $2K |
| 87077 | <1% | 313 | $1K | |
| 0012A | <1% | 95 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 234 | $1K |
| 81025 | <1% | 113 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 93 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 391 | $1K |
| 87081 | <1% | 66 | $1K | |
| 87807 | <1% | 31 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 189 | $1K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 26 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $976.32 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 27 | $964.16 |
| 0011A | <1% | 93 | $952.08 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 173 | $548.92 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 373 | $500.52 |
| 85379 | <1% | 39 | $479.51 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 40 | $478.56 |
| 83880 | <1% | 15 | $448.22 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 18 | $447.25 |
| 87186 | <1% | 28 | $353.05 | |
| 84703 | <1% | 35 | $342.06 | |
| 85652 | <1% | 39 | $271.52 | |
| 82947 | <1% | 48 | $241.31 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 18 | $222.04 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 13 | $199.86 |
| 86140 | <1% | 17 | $185.24 | |
| 83540 | <1% | 12 | $174.39 | |
| 85610 | <1% | 29 | $121.14 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEISENMANN, CLAUDA (CEO)